Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion

Retina

Volumn 26, Issue 8, 2006, Pages 896-901

  Goff, Mitchell J ^a   Jumper, J Michael ^a,b,c   Yang, Sam S ^a   Fu, Arthur D ^a,b   Johnson, Robert N ^a,b   McDonald, H Richard ^a,b   Ai, Everett ^a,b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b ST MARY S MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; ANAMNESIS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DRUG REEXPOSURE; EARLY TREATMENT DIABETIC RETINOPATHY STUDY VISUAL ACUITY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MALE; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA TEAR; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SUBCAPSULAR CATARACT; VISION; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLAUCOMA; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 33749622079     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000231543.45699.e1     Document Type: Review

References (21)

1. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-491.
2. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
3. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-772.
4. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427.
5. Larsson J, Zhu M, Sutter F, Gillies MC. Relationship between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806.
6. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136:419-425.
7. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997;12:99-109.
8. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
9. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315.
10. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth-factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16:398-406.
11. Central Vein Occlusion Study Group. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087-1095.
12. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M Report. Ophthalmology 1995;102:1425-1433.
13. Schindler RH, Chandler DB, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
14. McCuen B, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
15. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569.
16. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
17. Jonas JB, Degenring RF, Dreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112:593-598.
18. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 1005;40:63-68.
19. SCORE Study; www.clinicaltrials.gov; identifier NCT00105027.
20. Flynn HW, Scott IU. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease. It's time for clinical trials. Arch Ophthalmol 2005;123:258-259.
21. Blumenkranz MS. New therapy for central retinal vein occlusion. Are intravitreal steroids a possible answer? Arch Ophthalmol 2005;123:259-261.